Current status of vaccine development against leishmaniasis
- 公共卫生－已发表论文 
利什曼病是由利什曼原虫引起的一种人兽共患寄生虫病,分布于全球90多个国家,每年新发利什曼病患者130多万,有2万~3万例死亡,给全球尤其是发展中; 国家带来沉重的社会经济及医疗负担。目前针对利什曼病的防治措施主要为控制传染源和药物治疗,但均无法消除利什曼病。疫苗接种是行之有效的并具社会经济效; 益的控制利什曼病的防治手段。因此,利什曼病疫苗的研发具有十分重要的现实意义。本文重点就利什曼原虫致病机制及各类利什曼病疫苗的研究现状进行综述。Leishmaniasis is a zoonotic disease caused by Leishmania parasites.; Currently, leishmaniasis has affected 12 million people in over 90; countries, with 1.3 million reported cases each year and 20 -30 thousand; deaths. The disease causes a large social and economic burden; particularly in developing countries. Current strategies for; leishmaniasis control include controlling the source of infection and; drug treatment, both of which, however, cannot eliminate the disease.; Effective vaccination would be an ideal approach to control; leishmaniasis. Here, we review the pathogenic mechanism of Leishmania,; the existing vaccines for veterinary use, and human vaccine development; efforts against the disease.